ImmunityBio Announces Publication of Preclinical Data Demonstrating IL-15 Superagonist N-803 Improves Natural Killer-Mediated Tumor Cell Killing
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, a privately-held immunotherapy company, today announced the publication in Cancer Immunology, Immunotherapy of preclinical data demonstrating that ImmunityBio’s Anktiva™ (IL-15 superagonist also known as N-803) improves interferon-gamma (IFN-γ) production and killing of tumor of cells in vitro and in vivo by CD34+ progenitor-derived natural killer (NK) cells. Anktiva is currently being evaluated in late-stage clinical trials in combination with
